Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CAO Theodore Huizenga sold 1,283 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.57, for a total value of $17,410.31. Following the transaction, the chief accounting officer directly owned 67,863 shares in the company, […]

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) shares reached a new 52-week low during trading on Monday . The company traded as low as $13.80 and last traded at $13.8410, with a volume of 880219 shares changing hands. The stock had previously closed at $14.30. Wall Street Analyst Weigh In RARE has been the […]

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) was downgraded by stock analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research note issued to investors on Thursday, Briefing.com reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s price objective would indicate a […]